Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NASH Contender Inventiva Backed By Euronext IPO

Executive Summary

The five-year-old French biotech Inventiva Pharma has raised financing on the public markets to propel its lead fibrosis/NASH product through the development pipeline.

Advertisement

Related Content

Cirius Suspects Insulin Resistance Is Underlying Key To NASH
Intercept Increases Chance Of Success In NASH Without Significant Delay
Deal Watch: Arbor Betting On Building Horizant Commercially As Xenoport Couldn't

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098236

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel